The use ofSGLT-2 inhibitors or GLP-1 receptor agonists in patients withCVD and diabetes in clinical practice [43, 44, 45] are expected to reduce diabetes-inducedrisk. This evidence concerns the gene GLP1R and diabetes mellitus.